CRIP Researcher Publishes Collaborative Study on SARS-CoV-2 Variant

For the last several weeks, the news has been dominated not only by updates on the COVID-19 vaccine but also by a potential mutation in the SARS-CoV-2 virus. There is significant public concern about this variant, which emerged in Europe several months ago and was named D614G, but little research has been published thus far. A recent article in Science Magazine features a collaborative project between University of North Carolina at Chapel Hill and University of Wisconsin-Madison analyzing the effects of the mutation.

SJCEIRS Researcher Featured on NPR

Dr. Stacey Schultz-Cherry, a leading researcher at St. Jude CEIRS, was included in an interview with NPR science correspondent Joe Palca about approval for the Moderna COVID-19 vaccine. The interview focused on the science behind vaccine development and the approval requirements. New COVID-19 vaccines are being approved by the FDA through a process called an “emergency use authorization” in order to get them to vulnerable populations more quickly, so… Read more »

CRIP Investigators Publish Key SARS-CoV-2 Seroprevalence Findings

Several investigators from the Center for Research on Influenza Pathogenesis (CRIP), including Drs. Daniel Stadlbauer, Harm van Bakel, and Florian Krammer, completed a retrospective analysis of SARS-CoV-2 seroprevalence in New York City that has been accepted for publication by Nature. The study is based on a large and demographically diverse dataset that was assessed over several months during the first wave of… Read more »

Dr. Gavin Smith’s Research Featured in Reuters

Dr. Gavin Smith, of St. Jude CEIRS, discussed his recent COVID-19 research at Duke-NUS in Singapore. His group identified a variant of the SARS-CoV-2 virus that causes milder infections compared to the original virus. They found that patients infected with this variant had lower frequency of ICU admittance. Dr. Smith’s group also found that immune… Read more »

Dr. Sabra Klein Contributes to Scientific American Piece on COVID-19 Severity

Dr. Sabra Klein, a member of Johns Hopkins CEIRS, was recently interviewed for a piece published in Scientific American, exploring how and why COVID-19 is more likely to cause severe disease in some people compared to others. The article discusses the biological and social reasons why older people, men, people with chronic conditions, and people… Read more »

CEIRS Supports Reagent Development for COVID-19 Seroprevalence Study in Spain

The CEIRS Network’s response to the COVID-19 pandemic includes generation of resources, reagents, and information for both other members of CEIRS as well as the broader scientific community. Recently, reagents developed by Dr. Florian Krammer at the Icahn School of Medicine at Mount Sinai, part of the Center for Research on Influenza Pathogenesis (CRIP), were… Read more »

Dr. Peter Palese Publishes Pre-print Showing Proof-of-concept NDV-based Vaccine for COVID-19

Dr. Peter Palese, Professor at the Icahn School of Medicine at Mount Sinai and member of the Center for Research on Influenza Pathogenesis (CRIP), recently published a pre-print article describing a possible approach to developing a vaccine against SARS-CoV-2. The authors describe a proof-of-concept study where they inserted the immunogenic spike protein from SARS-CoV-2 into… Read more »

JHCEIRS Investigators Discuss COVID-19 on Bloomberg TV

Investigators from John Hopkins CEIRS, Lauren Sauer and Dr. Andrew Pekosz both recently appeared on the Bloomberg TV show Bloomberg Surveillance to talk about different aspects of the COVID-19 pandemic. Lauren Sauer, Assistant Professor in the Department of Emergency Medicine at Johns Hopkins, appeared on Bloomberg Surveillance on August 12, discussing the current status of… Read more »

JHCEIRS Investigators Receive Federal Funding for COVID-19 Plasma Trials

Drs. Andrew Pekosz and Sabra Klein of JHCEIRS are part of a collaboration at Johns Hopkins University that will evaluate the effectiveness of convalescent blood plasma therapy for COVID-19. The research team received $35 million in funding from the U.S. Department of Defense to support randomized clinical trials at twenty medical sites across the country…. Read more »